Abiraterone

BreastfeedingPediatric
  • TRADE NAME: Zytiga (Janssen Biotech)
  • INDICATIONS: Metastatic castration-resistant prostate cancer (in combination with prednisone)
  • CLASS: CYP17 inhibitor, Enzyme inhibitor
  • HALF-LIFE: 12 hours

FDA APPROVAL DATE: 04/28/2011

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Atazanavir, Carbamazepine, Clarithromycin, CYP3A4 inducers or inhibitors, Indinavir, Itraconazole, Ketoconazole, Nefazodone, Nelfinavir, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rifapentine, Ritonavir, Saquinavir, Telithromycin, Thioridazine, Voriconazole

PREGNANCY CATEGORY: X

Contra-indicated in women who are or may become pregnant.

Our database has 66 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
GENITOURINARY
HEMATOLOGIC
LOCAL
NEUROMUSCULAR/SKELETAL
OCULAR
RESPIRATORY
OTHER


Page last updated 06/12/2019

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top